I critique Baxter International's capital allocation decisions, stating the stock is not suitable for popular investment strategies. See why I rate BAX a sell.
That said, KCC also has a strong quality foundation; KCC built on the experience of a prior kidney model that demonstrated some quality benefits and also included specific quality improvement ...